It involves the anti trbc1 Federation domain, including: (a) VH domain, which has sequences selected from SEQ ID No. 9, 10, 11, 12, 13, 14, 15, 16, 17, 18； (b) VL domain, which has sequences selected from SEQ ID No. 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34. The union domain name is included in a variety of treatment formats, including a chemical antibiotic receptor (car),An antibody, an antibody drug copolymer, and a biospecific cell coupler. In addition, this joint domain operates as a selective agent to extract malignant cells that display tbc1 without affecting healthy cells that express tbc2, which is useful in the treatment of lymphoma or T-cell leukemia. It also refers to a nucleic acid, a vector, a cell that includes a car and a pharmacological component. It includes these forms of treatment.Referido a un dominio de union antigeno anti-TRBC1 el cual comprende: a) un dominio VH que tiene una secuencia que se selecciona de SEQ ID NO: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18； y b) un dominio VL que tiene una secuencia que se selecciona de SEQ ID NO: 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34. Dicho dominio de union esta comprendido en una diversidad de formatos terapeuticos, que incluyen un receptor antigenico quimerico (CAR), un anticuerpo, un conjugado anticuerpo-farmaco, y un acoplador bioespecifico de celulas T (BiTE). Ademas, dicho dominio de union funciona como un agente selectivo, extrayendo celulas T malignas que expresan TRBC1, sin afectar celulas T sanas que expresan TRBC2, siendo utiles en el tratamiento de linfoma o leucemia de celulas T. Tambien se refiere a un acido nucleico, un vector, una celula que comprende un CAR y una composicion farmaceutica que comprende dichos formatos terapeuticos mencionados.
